1. Home
  2. NOM vs BRNS Comparison

NOM vs BRNS Comparison

Compare NOM & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Missouri Quality Municipal Income Fund

NOM

Nuveen Missouri Quality Municipal Income Fund

BUY

Current Price

$11.00

Market Cap

25.9M

Sector

Finance

ML Signal

BUY

Logo Barinthus Biotherapeutics plc

BRNS

Barinthus Biotherapeutics plc

HOLD

Current Price

$0.63

Market Cap

24.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOM
BRNS
Founded
1993
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.9M
24.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NOM
BRNS
Price
$11.00
$0.63
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
8.9K
16.5K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
3.39%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.18
$0.51
52 Week High
$12.19
$2.91

Technical Indicators

Market Signals
Indicator
NOM
BRNS
Relative Strength Index (RSI) 47.88 54.45
Support Level $11.00 $0.56
Resistance Level $11.30 $0.76
Average True Range (ATR) 0.35 0.04
MACD 0.01 0.00
Stochastic Oscillator 6.00 44.49

Price Performance

Historical Comparison
NOM
BRNS

About NOM Nuveen Missouri Quality Municipal Income Fund

Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in the United States. The Fund's investment objective is current income exempt from both regular federal income taxes and Missouri personal income taxes, and to enhance portfolio value relative to the Missouri municipal bond market by investing in tax-exempt Missouri municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued. The fund invests in municipal securities as well as floating rate securities, and derivatives such as futures, options, and swap contracts to the necessary extent.

About BRNS Barinthus Biotherapeutics plc

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Share on Social Networks: